Agglomerative epigenetic aberrations are a common event in human breast cancer.
Agglomerative epigenetic aberrations are a common event in human breast cancer.
复制标题
DOI:
10.1158/0008-5472.can-08-1419
复制
发表时间:
2008-10-15
期刊:
影响因子:
11.2
通讯作者:
Futscher BW
中科院分区:
文献类型:
--
作者:
Novak P;Jensen T;Oshiro MM;Watts GS;Kim CJ;Futscher BW
Changes in DNA methylation patterns are a common characteristic of cancer cells. Recent studies suggest that DNA methylation affects not only discrete genes, but it can also affect large chromosomal regions, potentially leading to long range epigenetic silencing. It is unclear whether such long-range epigenetic events are relatively rare or frequent occurrences in cancer. Here we use a high-resolution promoter tiling array approach to analyze DNA methylation in breast cancer specimens and normal breast tissue to address this question. We identified 3506 cancer specific differentially methylated regions (DMR) in human breast cancer with 2033 being hypermethylation events and 1473 hypomethylation events. Most of these DMRs are recurrent in breast cancer; 90% of the identified DMRs occurred in at least 33% of the samples. Interestingly, we found a non-random spatial distribution of aberrantly methylated regions across the genome that showed a tendency to concentrate in relatively small genomic regions. Such agglomerates of hyper- and hypomethylated DMRs spanned up to several hundred kilobases and were frequently found at gene family clusters. The hypermethylation events usually occurred in the proximity of the transcription start site in CpG island promoters while hypomethylation events were frequently found in regions of segmental duplication. One example of a newly discovered agglomerate of hypermethylated DMRs associated with gene silencing in breast cancer that we examined in greater detail involved the protocadherin gene family clusters on chromosome 5 (PCDHA, PCDHB, and PCDHG). Taken together, our results suggest that agglomerative epigenetic aberrations are frequent events in human breast cancer.